Clinical Trial Update: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of dasatinib in patients with recurrent or metastatic head and neck cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Paranasal Sinus Cancer
• Salivary Gland Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Status: COMPLETED | Results posted: 2012-07-27